Table 2.

Prognostic value of H-FABP in studies recruiting exclusively patients with ‘confirmed’ acute coronary syndrome.

Author and year of publication	N	H-FABP assay	Clinical setting	MI (%)	Follow-up duration	Biomarkers measured	Key findings
Ishii et al. 200544	328	Dainippon	Consecutive CCU admissions, sample on admission	73.5%	6 mths	TnT	Increased H-FABP was independently associated with cardiac events (cardiac death or non-fatal MI) RR=9; p=0.0004
Erlikh et al. 200545	203	Hycult	Sample 6 h from symptom onset	NA	12 mths	TnI, CKMB	Elevated H-FABP was independent predictor of death or non-fatal MI, OR 2.45 95% CI (1.1–5.2); p=0.02
O’Donoghue et al. 200632	2287	In-house (Alere San Diego)	Clinical trial subset, mean time to randomisation = 41h	55%	10 mths	TnI, BNP, myoglobin	Elevated H-FABP was an independent predictor of death, recurrent MI, congestive heart failure or the composite of these end points (HR, 1.9; 95% CI, 1.3 to 2.7). In a multimarker approach, H-FABP, TnI, and BNP provided complementary information
Kilcullen et al. 200731	1448	Dainippon	Consecutive confirmed ACS, sample 12–24 h from symptoms	85%	12 mths	TnI, hsCRP	H-FABP predicts long-term mortality independent of GRACE clinical risk factors, troponin and hsCRP. The adjusted all-cause mortality HR among unstable angina patients (Trop-ve) was 11.35 (95% CI 2.00 to 64.34; p=0.006)